XSHE002390
Market cap951mUSD
Jan 14, Last price
3.92CNY
1D
1.03%
1Q
13.95%
Jan 2017
-60.36%
IPO
-17.30%
Name
Guizhou Xinbang Pharmaceutical Co Ltd
Chart & Performance
Profile
Guizhou Xinbang Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of Chinese herbal medicines and biological drugs in China and internationally. It offers cardiovascular and cerebrovascular, digestive system, endocrine, tumor and immune regulation, blood system, rheumatism and rheumatoid, urinary system, antipyretic analgesic, cold medication, gynecological treatment, and anti-infective drugs. The company was founded in 1995 and is headquartered in Guiyang, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 6,460,841 1.75% | 6,350,026 -1.88% | |||||||
Cost of revenue | 5,631,100 | 5,677,558 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 829,742 | 672,468 | |||||||
NOPBT Margin | 12.84% | 10.59% | |||||||
Operating Taxes | 42,249 | 44,977 | |||||||
Tax Rate | 5.09% | 6.69% | |||||||
NOPAT | 787,493 | 627,491 | |||||||
Net income | 287,233 28.02% | 224,374 -40.00% | |||||||
Dividends | (116,631) | (116,631) | |||||||
Dividend yield | 1.37% | 1.28% | |||||||
Proceeds from repurchase of equity | (141,401) | ||||||||
BB yield | 1.66% | ||||||||
Debt | |||||||||
Debt current | 796,285 | 1,345,754 | |||||||
Long-term debt | 42,249 | 44,046 | |||||||
Deferred revenue | 22,039 | 18,886 | |||||||
Other long-term liabilities | 308 | (238) | |||||||
Net debt | (307,921) | 146,781 | |||||||
Cash flow | |||||||||
Cash from operating activities | 790,618 | 590,797 | |||||||
CAPEX | (135,781) | ||||||||
Cash from investing activities | 50,259 | (118,021) | |||||||
Cash from financing activities | (908,180) | ||||||||
FCF | 1,142,760 | 655,092 | |||||||
Balance | |||||||||
Cash | 805,983 | 899,181 | |||||||
Long term investments | 340,472 | 343,839 | |||||||
Excess cash | 823,413 | 925,518 | |||||||
Stockholders' equity | 2,966,898 | 2,763,307 | |||||||
Invested Capital | 7,158,431 | 7,492,673 | |||||||
ROIC | 10.75% | 8.34% | |||||||
ROCE | 10.39% | 7.99% | |||||||
EV | |||||||||
Common stock shares outstanding | 1,914,885 | 1,943,852 | |||||||
Price | 4.44 -5.53% | 4.70 -36.66% | |||||||
Market cap | 8,502,091 -6.94% | 9,136,104 -32.31% | |||||||
EV | 8,483,855 | 9,539,481 | |||||||
EBITDA | 1,066,452 | 916,014 | |||||||
EV/EBITDA | 7.96 | 10.41 | |||||||
Interest | 40,485 | 51,788 | |||||||
Interest/NOPBT | 4.88% | 7.70% |